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ABSTRACT 
Background & Aims: Polycystic liver disease (PCLD) may lead to extensive 
hepatomegaly and invalidating complaints. Therapeutic decisions, including  
somatostatin-analogues (SA), (non)-transplant surgery are besides the existence of 
hepatomegaly, also guided by the severity of complaints. We developed and 
validated a self-report instrument to capture the presence and severity of disease 
specific complaints for PCLD.  
Methods:  The study population consisted of 129 patients. Items for the PCLD-
Complaint-Specific-Assessment (POLCA) were developed based on chart review of 
symptomatic PCLD patients (n=68) and literature; and discussed during expert-
consensus-meetings. 61 patients who needed therapy were asked to complete the 
POLCA and the Short Form Health Survey (SF-36Version2) at baseline and after 6 
months of SA-treatment. CT-scans were used to calculate liver volumes (LV). Factor 
analysis was conducted to identify subscales and remove suboptimal items. 
Reliability was assessed by Cronbach’s alpha. Convergent, criterion validity and 
responsiveness were tested using pre-specified hypotheses.  
Results: In the validation group (n=61), 47 received lanreotide (LAN) and 14 were 
offered LAN as bridge to liver transplantation (LTx). Factor analysis identified 4 
subscales which correlated with the Physical Component Summary (SF36). Baseline 
POLCA scores were significantly higher in LTx-listed patients. In contrast to SF36V2, 
POLCA paired observations in 47 patients demonstrated that 2 subscales lowered 
significantly and 2 borderline. LV reduction ≥120mL resulted in a numerical more 
pronounced relative decrease of all scores. 
Conclusions: In contrast to SF36V2, the POLCA shows good validity and 
responsiveness to measure complaint severity in PCLD.   
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Introduction   
Polycystic liver disease (PCLD) is a chronic inherited disorder in which numerous 
fluid-filled hepatic cysts are scattered throughout the liver. PCLD is the most frequent 
extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD). 
The second cause of PCLD is autosomal dominant polycystic liver disease (ADPLD), 
in which patients do not suffer from renal failure and only present with liver cysts. The 
natural history of PCLD, regardless of the genetic mutation, is similar [1-3]. Most of 
the patients with PCLD stay asymptomatic, but 2-5% of patients will develop 
symptomatic hepatomegaly as a result of the continuous increase in volume and 
number of liver cysts. The most frequently reported symptoms in the literature include 
abdominal distension, early satiety, abdominal pain, and finally severe malnutrition 
which can be lethal. Some of these patients develop portal hypertension, ascites or 
Budd-Chiari like syndrome, but these complications are rather uncommon [2].  
To reduce liver volume and improve complaints, several surgical techniques have 
long been the mainstream, including aspiration-sclerotherapy, laparoscopic or 
laparotomic fenestration and partial liver resection [4]. In patients with massive 
hepatomegaly and extreme invalidating symptoms, the only curative therapeutic 
option is liver transplantation (LTx) [5,6]. Pharmacological treatment of PCLD only 
became available five years ago. We and others showed that somatostatin-
analogues (SA), i.e. lanreotide and octreotide, decrease liver volume [7-10]. In 
addition, we recently demonstrated that a reduction of ≥120mL in liver volume after 6 
months has a high positive predictive value of improving complaints, a reduction 
which lies above the 95% upper limit of the confidence intervals of the differences in 
LV assessed by two software methods measuring the same LV [11]. Also mTOR 
inhibitors might reduce liver volume, although the data are less robust and 
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combination of octreotide and everolimus did not increase the LV reducing effect of 
octreotide alone [3,12].  
For the majority of patients, the hepatomegaly induced complaints represent the most 
important (referral) reason for medical or surgical treatment.   Until now, this 
evaluation is almost exclusively made by physicians in a non-standardized way. 
Currently, there is no disease specific questionnaire that (i) assesses presence, 
severity and impact of complaints in a standardized, valid way; (ii) can be used to 
assess the effect of pharmacological therapy; (iii) and finally is suitable to guide 
treatment decisions.  
We aimed to develop and validate a questionnaire, -the PCLD Complaint Specific 
Assessment (POLCA)-, intended to assess the specific complaints from the 
perspective of PCLD patients associated with hepatomegaly. 
 
Patients and methods  
In line with the FDA guidelines on development of patient reported outcome 
measures, we first established a conceptual framework in which we described the 
item generation process and psychometric properties (Supplementary materials A) 
[13,14]. In line with the conceptual framework on symptom experience of Leventhal 
and colleagues, the questionnaire should be able to capture both the presence as 
well as the severity of complaints [15,16].  
 
Study design 
Item selection and content validity: 
We constructed an exhaustive list of items likely to represent complaints of 
hepatomegaly that could be perceived by patients with symptomatic PCLD, using two 
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sources: (i) analysis of medical charts of 68 patients (creation group) referred for 
treatment between (1995-2007); and (ii) extensive literature search in Pubmed, 
extracting complaints of PCLD reported in studies published between January 1997 
and August 2010. Using search terms referring to the disease, its treatment forms 
and aspects of health-related quality of life, 15 articles were identified for data 
extraction [4,5,7,8,17-27]. 
In total, 27 candidate items were identified that were subsequently reviewed for 
relevance by an independent expert panel (3 hepatologists, 2 nephrologists, and 1 
abdominal transplant surgeon) and agreed upon during consensus meetings.  
Next, based on evidence on optimal scaling of self-report instruments, a 
questionnaire was created with labeled Likert-type responses ranging from 0 to 5 for 
presence (0= symptom not occurring; 5= symptom present all the time), as well as for 
severity (0= not; 5= extreme severe) [28]. All items in this questionnaire were then 
critically evaluated by the same 6 experts for clarity (ease of understanding). This 
resulted in 16 items being part of the “PCLD-Complaint-Specific-Assessment 
(POLCA)”, of which 9 items referred to occurrence, and 7 items referring to perceived 
severity of complaints. Since PCLD is a rare disease, pretesting of the questionnaire 
in symptomatic PCLD patients was not performed in order not to lose patients for the 
instrument’s validation. The POLCA is available in Supplementary Materials (B) and 
as an online calculator (http://www.uzleuven.be/en/polca) alongside the LV-index 
calculator.  
 
Validation group: 
The POLCA was administered to only  symptomatic PCLD patients (n=61) presenting 
at 2 different academic centers (University Hospitals KU.Leuven, Leuven and 
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Université Catholique de Louvain, Brussels) for treatment initiation of which 54 
participated in the open-label study to evaluate the safety and efficacy of LAN 90mg, 
including a dose escalation to LAN 120mg in case of non-responders (clinical 
trial.gov identifier NCT01315795). A multidisciplinary board consisting of 
hepatologists, nephrologists, abdominal transplant surgeons, psychologist and social 
workers discussed each case. Treatment options in this study considered were: (i) 
LAN 90 or 120mg every 4 weeks only; or (ii) LAN as a bridge to LTx. The latter group 
consisted of patients with a high subjective complaint burden due to hepatomegaly  
and who were considered not to be good candidates for other surgical interventions 
(e.g. Gigot type III or Mayo Modification D) [29,30]. Patients considered as 
candidates for combined liver-kidney transplantation (cLTKTx; n=5) were excluded to 
enhance the objectivity of hepatomegaly related complaints.  
The POLCA was administered to all patients prior to the choice of treatment and after 
6 months. All data were collected and retrospectively analyzed by a physician who 
was blinded for the multidisciplinary treatment decision at baseline and the patient’s 
medical characteristics.   
Informed consent was obtained from each patient. The use of the POLCA conforms 
to the ethical guidelines of the 1975 declaration of Helsinki as reflected in the a priori 
approval by the institution’s human research committee.   
 
Reliability and construct validity: 
Factor analysis was performed to determine whether the items measure a uni - or 
multidimensional concept. Next, reliability (internal consistency) of the subscales and 
total scale was determined by Cronbach’s alpha. To test for convergent validity, 
patients were administered the Short Form 36 Version 2 (SF36V2) at baseline 
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alongside the POLCA. The SF36V2 is a wildly used, norm-based validated survey 
that measures health status on 8 health domains (physical functioning, physical role 
functioning, bodily pain, general health perceptions, vitality, emotional role 
functioning, social role functioning, mental health). A physical component summary 
(PCS) and mental component summary (MCS) can be calculated [31,32]. We 
hypothesized that the POLCA subscales would correlate moderately with the more 
physically oriented health status domains, with correlation coefficients above 0.3 
indicating good convergent validity. In view of known-groups validity, we 
hypothesized that patients on the waiting list for LTx will have higher POLCA 
subscale scores than patients not (yet) considered for transplantation.  
 
Criterion validity:  
In order to determine the POLCA’s concurrent validity, we hypothesized that patients 
with more complaints also had a larger liver. Therefore, at time of POLCA 
completion, a CT-scan without contrast enhancement was performed to calculate 
liver volume and kidney volumes. The CT-scans were performed on different multi-
detector CT-scanners: Siemens Somatom Sensation 64 and Siemens Somatom 
Definition Flash (University Hospitals, KULeuven, Siemens Medical Solutions AG, 
Erlangen, Germany) and Spiral/Helical CT Brilliance 64 (Philips) (Université 
Catholique de Louvain, Brussels). Volumes were calculated by using Volume® 
(Siemens; Erlangen, Germany) by 2 radiologists who were blinded for the 
questionnaire data and treatment decision [11].  
The LV was also ‘normalized’ to an enlargement index (LV-index) which gives an 
idea how many times the liver is enlarged for the individual patient (LV-index=liver 
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volume (mL) (CT-scan)/((706.2*body surface area)+2.4)) [33]. We anticipated a 
moderate to strong correlation (r>0.50) as proof of concurrent validity.  
Responsiveness: 
We hypothesized that changes in subscales of the questionnaire between baseline 
and month 6 were detectable and significant as a result of the pharmacological 
treatment. In addition, based on our previous observations, we also hypothesized 
that a reduction of ≥120mL in LV after 6 months of SA-treatment results in a more 
pronounced effect on the perceived complaints [12]. 
  
Statistical analysis 
Analysis of internal consistency was evaluated with Cronbach’ alpha, with value >0.7 
and  <0.9 indicating excellent reliability. To analyze whether they were at least some 
correlations amongst the 16 POLCA items so that coherent factors are allowed to be 
identified, factorability was assessed by measures of sampling adequacy (Kayser-
Mayer-Olkin>0.5). Factor analysis on Eigenvalues was performed to identify 
subscales and remove suboptimal items, in which an Eigenvalue < 1 does not have 
enough total variance explained to represent an unique factor. To facilitate the 
interpretation of extracted correlated factors, Promax rotation was used. Differences 
in characteristics between groups were analyzed by an independent t-test (two tailed) 
or Mann-Whitney U Test, where appropriate. In order to evaluate responsiveness of 
the POLCA over time, a paired sample t-test was used. To describe correlations, 
non-parametric testing by Spearman was performed. To compare percentages of 
observations between groups, Chi-square testing was used. Data are presented as 
mean with standard deviation (SD) or standard error (SE), unless otherwise 
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specified. All statistics were performed in SPSS version 19 (SPSS Inc, Chicago, IL, 
USA). A p-value< 0.05 was considered as statistically significant. 
 
Results  
Study population 
The characteristics of the creation and validation group are presented in Table 1.  
Creation group: Data from 68 patients who were treated because of symptomatic 
PCLD between 1997 and 2010 were extracted. There were 60 women (88%). 60 
patients were diagnosed with ADPKD.  49 women and 11 men were diagnosed with 
ADPKD. 
Validation group:  Between January 2011 and August 2013, 61 symptomatic PCLD 
patients completed the POLCA at baseline. All patients were started on SA of which 
14 were multidisciplinary evaluated as LTx candidates. Patients were given LAN 
90mg or 120 mg/4 weeks during at least 6 months. Patients considered as LTx 
candidates were significant younger than patients in the other group, in which ages 
were respectively 47y (SD:8.1) and 52y (SD:8) (Independent t-test p=.04). Mid-upper 
arm circumference (cm) for both groups were respectively: 24.8 (SD: 2.8) and 25.8 
(SD: 2.8) (p=0.3).  
 
Validity  
Factor analysis and reliability:  
Kayser-Meyer-Olkin measure of Sampling adequacy was 0.73. Factor analysis 
yielded 3 subscales related to complaint experience explaining 55% of the total 
variance, i.e. (i) gastro-oesophagal reflux disease (GERD) related complaints (4 
items), (ii) impact on food intake (2 items); and (iii) perception of enlarged liver 
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volume (3 items). Cronbach’s alpha for the 9 items measuring symptom experience 
was 0.81, with alpha’s for the 3 subscales being 0.81, 0.74 and 0.64 respectively, 
and 0.86 for the total scale, indicating satisfactory reliability. Pattern matrix clustered 
all items that highly loaded on each factor. Factor loading, expressing the correlation 
of the item with the factor, was at least 0.39. Figure 1 represents the items referring 
to the different subscales. Sum scores for the 3 factors and for the 7 items referring 
to ‘severity of perceived illness’ were calculated and used for further statistical 
analysis. Minimum-maximum scores for each subscale were: (i) severity of perceived 
illness: 0-35; (ii) GERD related complaints: 0-20; (iii) impact on food intake: 0-10; (iv) 
perception of enlarged liver volume: 0-15. Spearman correlation coefficients between 
all 4 item groups ranged from 0.24 to 0.45. The higher the score, the higher the 
complaint experience or severity.  
 
Convergent validity: 
All subscales showed moderate to good correlations with some SF36V2 subscales, 
as well as with the Physical Component Summary (Table 2). Spearman correlations 
ranged from -0.3 to -0.7, providing evidence for convergent validity of the POLCA. 
Correlations with the other subscales, i.e. emotional role, mental health as well as 
with the Mental Component  Summary, were weak and not significant. 
 
Known-groups validity: 
With the exception of impact on food intake, all subscale sum scores were 
significantly lower in symptomatic patients treated with SA only (n=47) compared to 
patients listed for LTx (n=14), indicating known-groups validity. The LV-index in both 
groups was respectively 4 (SD:1.5) and 5 (SD:1.7) (Independent t-test; p=.04), 
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reflecting that a more enlarged liver induces more complaints. The results of the 
POLCA subscales and SF36V2 of both groups are given in Table 3. 
 
Concurrent validity: 
We could not observe significant linear correlations between total scores of POLCA 
subscales and LV-index or liver volume at baseline, indicating a lack of concurrent 
validity. Health domains and summary scores of the SF36V2 did not correlate with 
liver volumes either.  
 
Responsiveness:  
For 47/61 patients (77%) (LTx group: n=7; no-LTx group n=40), paired observations 
(i.e. baseline and month 6) regarding LV, SF36V2 and POLCA were available.  
The baseline characteristics of these patients were: (i) women (n=43); (ii) ADPKD 
(n=40); (iii) age 51y (SD:1.2); (iv) LV-index: 4.1 (SE:0.2). Dropout reasons (n=14) 
were: underwent LTx (n=5); SA related side effects (n=2); missing item data (n=7). 
Overall absolute LV reduction was -116mL (SD:411). Despite a borderline significant 
increase in general health (p=0.06) and physical component summary (p=0.07), none 
of the SF36V2 health domains significantly changed after 6 months. In contrast, two 
of the 4 POLCA subscales significantly decreased over time, indicating 
responsiveness to treatment, with scores on the 3th and 4th subscale being 
borderline significant (Figure 2).  
LTx patients versus no-LTx patients: 
The POLCA changes in time in the no-LTx group  (n=40) and the LTx -group (n=7) 
were different and are given in figure 3. In the LTx group, LV increased with 90mL 
(SE:246) whereas in the no LTx group LV decreased with 246mL (SE: 52) (p=0.1).  
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Patients with changes in LV ≥120mL versus <120mL: 
In 20/47 (43%) a reduction of at least 120mL in LV was observed, which was in 
accordance with a significant reduction in total scores of 2 POLCA subscales e.g. (i) 
severity of perceived illness and (ii) GERD related complaints (paired t-test; 
respectively: p=0.04 and 0.001). The relative reductions in means of total scores 
were numerical more pronounced compared with the patient group not meeting this 
volume reduction (Table 4).  
 
Discussion 
In the present study we developed and psychometrically validated the POLCA 
questionnaire, specifically designed to capture the presence and the severity of 
hepatomegaly-related complaints from the perspective of patients with symptomatic 
polycystic liver disease. Complaints expressed by PCLD patients and their 
interpretation by clinicians in terms of severity and impact on the health related 
quality of life (HRQL) is subjective, yet, highly relevant as decisions on medical 
treatment and even indication for LTx in PCLD, are partially based on the severity of 
complaints.  
Because of their subjective nature, it is crucial that complaints related to 
hepatomegaly can be assessed in a standardized, validated way. The POLCA is an 
easy to use, disease-specific complaint instrument that might assist in determining 
the best care for symptomatic patients as it is reliable, valid and sensitive, as shown 
by the present study.  
Available treatment options aim to reduce LV, either by the administration of SA or 
(non)-Tx surgery, and alleviate its associated complaints. Studies thus far only 
evaluated HRQL in relation to cyst fenestration and LTx as an outcome in PCLD 
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patients [23,24,34]. Although improvement was seen in some HRQL domains using 
the SF36 version1 in the two randomized placebo controlled trials, the extent to 
which SA ease complaints using non-disease specific questionnaires remained 
unclear [7,8]. In another study, patients were asked whether their complaints 
changed after 6 months of SA treatment, but no validated questionnaire documenting 
changes in specific complaints was used [11]. By using chart review, literature review 
and expert input, we ensured that the POLCA evaluates all complaints that patients 
with PCLD can experience as a result of hepatomegaly as proof of content validity. 
Construct validity was demonstrated by the moderate to high correlations with the 
Physical Composite score of the SF36 V2, reflecting the disability caused by 
complaints on patients physical functioning. No significant correlation with the Mental 
Composite Score was observed, suggesting that the higher symptom burden was not 
the result of mental problems such as e.g. depression. Furthermore, the Physical 
composite score was significantly lower in LTx-group compared to no-LTx patients. 
There was in this subgroup also no difference in Mental Composite scores. These 
results are important as one wants to be sure that complaints experienced are the 
result of a medical condition such as hepatomegaly, and not by underlying mental 
problems.  
We could not observe a linear correlation between POLCA scores and LV, which is 
from a clinical point of view not unexpected. We demonstrated that especially young 
women with higher LV-indices displayed more complaints. In this regard, we 
postulate that changes in LV per time unit rather than a given LV account for 
complaint experience and severity.  
As proof of known-groups validity, we further demonstrated (i) that patients listed for 
LTx had significantly higher scores on all POLCA subscales, which was in 
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accordance to a significant more pronounced enlargement of the liver. In addition, we 
founded that the POLCA changes in time under SA treatment were different for LTx 
candidates versus those who were not. In this regard, the POLCA scores and the 
changes in time could play a role in the multidisciplinary approach for treatment 
decision of symptomatic PCLD patients, as the impact of their hepatomegaly on their 
symptom experience and impact on daily functioning might help to better determine 
the timing of starting medical therapy and assess its efficacy and effectiveness, or 
considering (non)-Tx surgery.  
This study demonstrates that the POLCA is able to standardize complaints in PCLD 
patients, on the other hand we are convinced that also other factors play their role in 
the orchestration of the therapeutic approach and that the management of PCLD 
requires a multidisciplinary approach. A schematic overview of an objective 
assessment of symptomatic PCLD patients is presented in Figure 4.  
In this stadium of validation of this self report instrument, we excluded the data of 5 
patients considered as cLTKTx candidates to construct the POLCA. Since the 
decision for single KTx versus cLTKTx in ADPKD with end stage renal disease is an 
important issue, we also analyzed the data of these 5 patients separately in view of 
our findings (for details; see Supplementary Materials C). Their results suggest that 
the POLCA might also be of value in this subpopulation. However, the group was too 
small to draw firm conclusions. 
The following study limitations should be acknowledged. First, this was not a placebo 
controlled trial and patients in the validations group were aware of the potential effect 
of SA treatment at study enrollment. Second, the sample size used to validate the 
POLCA is relatively small. PCLD, however, is a rare disorder, limiting the possibility 
of large samples. Third, no a-symptomatic patients were available, as the study was 
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conducted at tertiary referral centers. No registry of patients exists today, limiting our 
options to reach out to other (a)symptomatic patients. Fourth, there has been some 
debate as whether or not to include dyspnea as a hepatomegaly-related complaint. 
Given that there is no correlation with objective lung function testing and that 
dyspnea can be related to other extra-hepatic causes, it was decided not to include 
this complaint. Fifth, although 3 questions of the POLCA refer to nutrition (i.e. 
appetite, early satiety, and impression on body weight evolution), objective 
assessment of the nutritional status in PCLD is warranted. The mid-upper arm 
circumference is currently used as a gold standard to assess malnutrition as it 
reflects lean body mass. However, other more objective techniques should be 
evaluated in the future such as the calculation of total muscle mass at lumbar 3 level 
to assess the prevalence of sarcopenia and identify PCLD specific risk factors for 
poor nutrition complementary to the POLCA [35,36].  Finally, although validity was 
tested in a comprehensive way, other hypotheses could have been considered.  
The validation of self-report instruments is however a complex, continuous process; 
and there is obviously a need for further studies. Multicenter studies need to be 
assessed in order to confirm our findings with the inclusion of other treatment options 
considered in symptomatic PCLD such as patients who are candidates for combined 
liver and kidney transplantation and in the selection and follow-up of patients who are 
candidates for non-LTx surgery.  
In conclusion, the POLCA is an easy, reliable, valid and sensitive self-report 
questionnaire to evaluate the presence and severity of hepatomegaly-related 
complaints of patients with PCLD. This questionnaire can be embedded both in 
research and clinical care, as it (i) allows tracking the natural evolution of 
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hepatomegaly-related complaints over time; (ii) can guide treatment decisions; and 
(iii) facilitates the evaluation of treatment effects over time.   
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Figure legends 
Fig. 1. Overview of the POLCA with the 16 items. According to the conceptual 
framework 9 items reflect presence (item scoring: 0= symptom not occurring; 5= 
symptom present all the time) and 7 items represent severity of perceived illness 
(item scoring: 0= not; 5= extreme severe). Factor analysis on complaint experience 
recognized 3 subscales. The minimum and maximum scores for each subscale 
presented are: (i) severity of perceived illness: 0-35 (7 items)  (ii) Gastro-oesophagal 
reflux disease related complaints: 0-20 (4 items), (iii) Impact on food intake: 0-10 (2 
items); (iv) Perception of enlarged liver volume: 0-15 (3 items). 
Fig. 2. Overall responsiveness analysis of the 4 POLCA subscales and the 2 
summary components (SF36V2) (n=47). (A) Severity of complaints (range: 0-35); 
(B) Gastro-oesophagal reflux disease (GERD) related complaints (range: 0-20); (C) 
Impact on food intake (range: 0-10); (D) Perception of enlarged liver volume (range: 
0-15); (E) Physical component summary (range: 0-100) (F) Mental component 
summary (range: 0-100). Data presented as mean (± standard error of mean). 
Fig. 3. Paired observations of the 4 POLCA subscales in patients listed for LTx 
(dashed line: n=7) and patients receiving somatostatin analogues only (full 
line; n=40). (A) Severity of complaints (range: 0-35); (B) Gastro-oesophagal reflux 
disease (GERD) related complaints (range: 0-20); (C) Impact on food intake (range: 
0-10); (D) Perception of enlarged liver volume (range: 0-15). Data presented as mean 
(± standard error of mean). P value represents the group*factor interaction. 
Fig. 4. Flow chart for an objective assessment of patients with symptomatic 
PCLD and therapeutic possibilities.  
 
  
  
  
  
  
Tables 
Table 1 Baseline demographic and clinical characteristics of the study population. 
Characteristics Creation group (n=68) Validation group (n=61) 
ADPKD/ ADPLD 60/8 50/11 
Age (Y) (SD) 
       female (Y) (SD) 
        male  (Y) (SD) 
52 (±7.7)  
51.5 (±7.9) (n=60) 
56 (±6) (n=8) 
51  (±8.5)  
50 (±8) (n=55) 
57.5 (±9.5) (n=6) 
Age diagnosis (Y) (SD) NA 36 (±10.5) 
Age onset  complaints (Y) (SD) NA 47 (±11) 
Liver volume (mL) (IQR) 4355 (2906;6200) 4945 (3814;7300) 
Liver volume-index (SD) 3.8 (±1.7) 4.2 (±1.6) 
Kidney volume mL (IQR) (ADPKD) 887 (417;1792) (n=60) 1126 (586;1806) (n=55) 
Glomerular filtration rate (MDRD) 
       ADPKD ml/min/1.73m² (IQR) 
       ADPLD ml/min/1.73m² (IQR) 
 
48 (17;71) 
                 82 (73;96) 
  
                  58 (43;75) 
85 (71;91) 
MUAC  (cm) (SD) NA 25.5 (2.8) 
    Legend: ADPKD: Autosomal Dominant Polycystic Kidney  disease; ADPLD: Autosomal  Dominant Polycystic Liver Disease;                
                    NA: not assessed;  GFR: glomerular filtration rate; MDRD: Modification of Diet in Renal Disease 
                    Liver volume index = LV (imaging)/((706.2 x body surface area)+2.4); MUAC: mid-upper arm circumference 
 
 
 
 
 
 
 
  
 
Table 2 Spearman correlations between POLCA and SF36V2 health domains.  
 
Legend: GERD: gastro-oesophagal reflux disease; LV: liver volume; NS: not significant.  
               *p<.1; **p<.05; ***p<.01. 
 
 
 
 
 
 
                                     
                         POLCA  
 
SF36V2  
Severity of 
perceived 
illness 
GERD 
related 
complaints 
Impact on 
food intake 
Perception 
of enlarged 
LV 
Physical functioning -0.3** NS -0.27* -0.3** 
Physical role 
functioning 
-0.4*** -0.5*** -0.26* -0.56*** 
Bodily pain -0.4*** -0.47*** NS -0.6*** 
General health -0.33** -0.48*** NS -0.473*** 
Vitality -0.32** NS NS -0.35** 
Social functioning -0.49*** NS -0.4*** -0.281* 
Emotional role 
functioning 
NS NS NS NS 
Mental health NS NS NS NS 
Physical component 
summary 
-0.45*** -0.55*** -0.34** -0.53*** 
Mental    component 
summary 
NS NS NS NS 
  
Table 3 Comparison of POLCA subscales and SF36V2 health domains between 
patients not (yet) considered as LTx candidates (no-LTx group) versus patients 
considered as LTx candidates (LTx group).  
 
 No-LTx group 
(n=47) 
LTx group 
 (n=14) 
       P  
POLCA 
Severity of perceived illness 16.8 (±6) 20.3 (±4.3) 0.049* 
GERD related complaints  2 (0.25;4) 5 (2;7) 0.03** 
Impact on food intake 3.7 (±2.5) 4.9 (±3.2) 0.15* 
Perception of enlarged LV 7(5-9) 8 (8-11) 0.006** 
SF36V2 
Physical component summary 42 (±9.7) 33 (±8.3) 0.007* 
Mental component summary 45.5 (41;53) 41 (28;52.5) 0.2 
Legend:  LTx: liver transplantation; GERD: gastro-oesophagal reflux disease; LV: liver volume 
Data presented as mean (SD) and median (IQR) where appropriate.  
*Independent t-test; ** Mann-Whitney U statistic. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 4 Mean scores (±SD) of the POLCA subscales at baseline and after 6 months 
of treatment with lanreotide. A more pronounced relative reduction in differences of 
mean in all subscales can be observed in patients with a reduction ≥120mL after 6 
months.  
Legend: GERD: gastro-oesophagal reflux disease; LV: liver volume; NS: not significant.  
               * Chi-square. 
 
 
 
 
 
 
 
 
 
 
POLCA  
Change liver volume 
≥120mL 
  n=20 
Change liver volume 
<120mL 
n=27 
 
Baseline Month 6 Change Baseline Month 6 Change P* 
Severity of perceived illness  15.2 (±5.4) 12.4 (±6) -19% 18.5 (±6.0) 16 (±6.0) -13% NS 
GERD related complaints 2.2 (±2.2) 0.9 (±1.1) -59% 4.8 (±4.9) 3.7 (±4.1) -23% .03 
Impact on food intake 3.3 (±2.1) 2.7 (±2.1) -18.2% 3.9 (±2.6) 3.5 (±2.6) -10.3% NS 
Perception of enlarged LV 6.4 (±2.8) 5.5 (±3.3) -14% 7.5 (±3) 7 (±3.5) -6% NS 
